Trial Profile
A Novel Reversible Albumin-Binding Growth Hormone Derivative Possesses a Promising Once-Weekly Treatment Profile in Aghd
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Feb 2015
Price :
$35
*
At a glance
- Drugs Somapacitan (Primary) ; Somatropin
- Indications Growth disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Novo Nordisk
- 20 Feb 2015 New trial record